Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Chinese Journal of Cancer》 2006-04
Add to Favorite Get Latest Update

Efficacy of Rituximab-containing Regimens on Indolent B-cell Lymphoma-a Report of 34 Cases

XIA Zhong-Jun1,2, WANG Feng-Hua1,2, HUANG Hui-Qiang1,2, LUO Hui-Yan1,2,LI Yu-Hong1,2, LIN Tong-Yu1,2, JIANG Wen-Qi1,2, GUAN Zhong-Zhen1,21. State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China2. Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, P. R. China  
BACKGROUND OBJECTIVE: The efficacy of rituximab given alone or in combination with chemotherapy on naive or relapsed indolent lymphoma is good. This study was to investigate the efficacy and safety of rituximab-containing regimens for patients with indolent B-cell lymphoma in China. METHODS: From Mar. 1999 to Jan. 2005, 34 patients with indolent B-cell lymphoma received rituximab-containing regimens with a median of 5 cycles (ranged from 3 to 8 cycles). Of the 34 patients, 2 received rituximab alone, and 32 received rituximab-based regimens, which including CHOP (16 cases), FMD (5 cases), CHOPE (4 cases), EPOCH (2 cases), DICE (2 cases), DAHP (2 cases), and FN (1 case). RESULTS: Of the 34 patients, 30 were evaluable for objective response. The overall response (OR) rate was 93.3%, and the complete response (CR) rate was 60.0%; the OR rate and CR rate of 22 evaluable naive patients were 95.4% and 66.7%, those of 18 evaluable follicular lymphoma patients were 88.9% and 66.7%. With a median follow-up of 17 months (4-68 months), the 1-year progression-freely survival rate was 85.3%. Myelosuppression was the major adverse event: 19 patients suffered from leukopenia with 4 cases of grade Ⅲ-Ⅳ event, 5 suffered from thrombocytopenia with 4 cases of grade Ⅲ-Ⅳ event, and 2 suffered from febrile neutropenia. Other adverse events included grade Ⅰ-Ⅱ nausea/vomiting, mild alopecia, and transient liver function abnormality. The infusional reaction of rituximab consisted of grade Ⅰ-Ⅱ rigor/febrile, skin rash, mild hypotension, and asymptomatic ventricular premature beat. CONCLUSION: Rituximab-containing chemotherapeutic regimens are effective for indolent B-cell lymphoma with mild toxicity.
【CateGory Index】: R733.1
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
Chinese Journal Full-text Database 4 Hits
1 PAN Meng1,2,KONG Yun1,CHENChang3,GULi1(1.School ofLife Science,Shandong University,Jinan250100,China;2.Beijing Reclaimed Water Ltd.,Bejing100078,China;3.School ofLife Science and Technology,Beijing UniversityofChemicalTechnology,Beijing100029,China);Research progress of monoclonal antibody drugs[J];Chinese Journal of Biochemical Pharmaceutics;2008-01
2 ZHANG Shige (Depart.of Pharmacy,Beijing Jishuitan Hospital of Beijing University,Beijing 100035,China);Clinical Evaluation and Development of Antineoplastic Monoclonal Antibody[J];Evaluation and Analysis of Drug-Use in Hospitals of China;2007-01
3 DING Xiu-zhi,LI Guo-shi.Maoming Chinese Traditional Medical Hospital,Guangdong,Maoming(255000);Clinical observation of rituximab and ESHAP regiment in the treatment of relapsed non-Hodgkin Lymphoma[J];China Practical Medicine;2012-18
4 HAN Xia, WANG Huaqing, LIU Xianming, QIU Lihua, ZHANG Huilai, QIAN Zhengzi, LI Wei, CUI Xiuzhen, HAO Xishan Department of Lymphoma, Cancer Institute and Hospital of Tianjin Medical University, Tianjin 300060, China;Clinical Analysis of the Effect of Rituximab in Combination with CTOP Chemotherapy on B Cell Non-Hodgkin's Malignant Lymphoma[J];Chinese Journal of Clinical Oncology;2010-06
China Proceedings of conference Full-text Database 1 Hits
1 ;美罗华联合CTOP方案治疗B细胞非霍奇金淋巴瘤35例临床分析[A];[C];2009
Chinese Journal Full-text Database 10 Hits
1 LIN Tong-Yu1,2, ZHANG Hong-Yu1,2, HUANG Yan1,2, GUAN Zhong-Zhen1,2, SHEN Ti3, SHI Yuan-Kai4, ZHU Jun5, KE Xiao-Yan6, WANG Hua-Qing7, SHEN Zhi-Xiang8, YU Shi-Ying9, LIU Ting10, SHI Xiao-Li11 1. Skate Key Laboratory of Oncology in Southern China, Guangzhou, Guangdong, 510060, P. R. China 2. Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, P. R. China 3. Department of Hematology, Union Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, 100730, P. R. China 4. Department of Medical Oncology, Cancer Center, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, 100021, P. R. China 5. Department of Hematology, Beijing Cancer Hospital, Beijing, 100036, P. R. China 6. Department of Hematology, The Third Affiliated Hospital, Peking University, Beijing, 100083, P. R. China 7. Tianjin Cancer Hospital, Tianjin, 300060, P. R. China 8. Department of Hematology, Ruijin Hospital, Shanghai Second Medical University, Shanghai, 200025, P. R. China 9. Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, P. R. China 10. Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, P. R. China 11. Hangzhou Tigermed consulting Co, Ltd, Hangzhou, Zhejiang, 310012, P. R. China;Comparison between R-CHOP Regimen and CHOP Regimen in Treating Naive Diffuse Large B-cell Lymphoma in China -- a Multi-center Randomized Trail[J];Chinese Journal of Cancer;2005-12
2 HUANG Hui-Qiang1,2, BU Qing1,2, XIA Zhong-Jun1,2, LIN Xu-Bing1,2, WANG Feng-Hua1,2,LI Yu-Hong1,2, PENG Yu-Long1,2, PAN Zhan-He1,2, WANG Shu-Sen1,2, LIN Tong-Yu1,2,JIANG Wen-Qi1,2, GUAN Zhong-Zhen1,21. State Key Laboratory of Oncology in South China, Guangzhou, Gongdong, 510060, P. R. China2. Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Gongdong, 510060, P. R. China;Efficacy of Rituximab-containing Salvage Regimens on Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma[J];Chinese Journal of Cancer;2006-04
3 AI Xiao-Hong1, TANG Xiao-Qing2, LIU Yan-Ping1, LIU Hua-Qing3, DONG Lin3 1. Department of Oncology, The First Affiliated Hospital, Nanhua University, Hengyang, Hunan, 421001, P. R. China 2. School of Pharmaceutical Science, Central South University, Changsha, Hunan, 410078, P. R. China 3. Cancer Institute, Nanhua University, Hengyang, Hunan, 421001, P. R. China;Effect of Neferine on Adriamycin-resistance of Thermotolerant Hepatocarcinoma Cell Line HepG2/thermotolerance[J];Chinese Journal of Cancer;2007-04
4 Ma Yongyong Department of Hemotology,The First Affliated Hospital of Wenzhou Medical College (325027),China;The Effects of Res on Expression and Secretion of IL-8 and VEGF of Lymphoma Raji Cells[J];Journal of Zhejiang University of Traditional Chinese Medicine;2008-06
5 Wang Jie,Li Jianguo,Pang Hua,Lei Chengming,Peng Zhiping,Li Shaolin (Department of Nuclear Medicine,First Affiliated Hospital of Chongqing Medical University,Chongqing,400016,China);Preparation of human anti-HIF-1α scFv of lung adenocarcinoma and its radioimmunoimaging[J];Acta Academiae Medicinae Militaris Tertiae;2010-17
6 ZHENG Hang,CHEN Jin-zhang,LIAO Wang-jun,LUO Rong-cheng Center of Oncology,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China;Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer[J];Journal of Southern Medical University;2006-05
7 CHI Xiao-hua,HUANG Bao-dan,WANG Bing,HUANG Kai,LI Gui-ping Department of Nuclear Medicine,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China;IgG radiolabelling with ~(99m)Tc by tricarbonyl method and its biodistribution in mice[J];Journal of Southern Medical University;2010-12
8 GAO Guofu *, YAO Shuxiang, SUN Xiudi, CHANG Runsheng, JIANG Yong, LUO Xuechang, JIN Ping, QIAO Youlin. * Cancer Institute, Chinese Academy of Medical Sciences, Beijing 100021, P.R.China;Establishment of cohort to study lung cancer in Yunnan tin miners[J];Chinese Journal of Lung Cancer;2002-02
9 HUANG Feng DENG Xiao-hu ZHANG Jiang-lin LIANG Dong-feng GUO Jun-hua LI Sheng-guang ZHU Jian LI Xiao-feng.Department of Rheumatology,Chinese PLA General Hospital,Beijing 100853,China.;Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:a randomized,double blind,controlled trial[J];Chinese Journal of Rheumatology;2006-09
10 Li Guiping,Huang Kai,Liu Feng,et al.Department of Nuclear Medicine,Nanfang Hospital,Southern Medical University,Guangzhou,Guangdong(510515),China;Study on Pretargeting of Inflammation-Site and Imaging with Avidin-Biotin System[J];Journal of Radioimmunology;2009-05
【Secondary References】
Chinese Journal Full-text Database 10 Hits
1 Wang Bing,Li Gui-ping,Huang Bao-dan,et al. Department of Nuclear Medicine,Nanfang Hospital,Southern Medical University,Guangzhou(510515),China;The Distributional Experiment of ~(99m)Tc Radiolabelled DTPA-biotin and hIgG in Normal Mice[J];Journal of Radioimmunology;2012-04
2 Xiong Xiaochun.et al Pharmacy College,zhengzhou University(zheng zhou 450001);Research Progress of Resveratrol on Anti-tumor[J];Heilongjiang Medicine Journal;2010-01
3 Zheng Xiao-wei,Zhou Li-ming(Department of Pharmacology,Preclinical and Forensic Medical School,West China Medical Center,Sichuan University,Chengdu 610041);The progress of research with antitumor drug[J];Sichuan Journal of Physiological Sciences;2007-04
4 SHEN Hong1,YI Yu1,MEI Jian-feng1,ZHU Ke-yin2,LI Min1,YING Guo-qing1(1.School of Pharmaceutical Science,Zhejiang University of Technology,Hangzhou 310014,China;2.BIOLINK Biopharm,Co.,Ltd.,Hangzhou 310018,China);Preparation and purification of monoclonal antibodies against human chorionic gonadotrophin[J];Chinese Journal of Biochemical Pharmaceutics;2010-01
5 ZHANG Yong-chen,WEN Jian,ZHANG Liang,ZHAO Lei(The N0.2 Hospital Affiliated to Southeast University,Nanjing 210003,China);Preparation and identification of anti-HIV-1 gp120 monoclonal antibody[J];Chinese Journal of Biochemical Pharmaceutics;2010-01
6 HAO Lei-lei,ZHANG Dian-rui(School of Pharmaceutical Science,Shandong University,Jinan 250012,China);The research progress of monoclonal antibody immuno-nanoparticles[J];Chinese Journal of Biochemical Pharmaceutics;2012-02
7 LI Ping,JIANG Lin,MA Ya-ru,et al(Lanzhou Institute of Biological Products,Lanzhou 730046,China);Preparation and Identification of Murine Monoclonal Antibody against TNF-α[J];Chinese Journal of Biologicals;2008-12
8 LIU Ya-nan,WU Jian-guo,MI Xian-qiang,CHEN Xiao-hong,CAO Chuan-ping,ZHU Jun-feng,GUAN Yan-qing,SONG Hong-mei,TANG Liang,ZHENG Ling-li,JU Dian-wen,TAO Qun(Shanghai Mayer Biotech Co.Ltd,Shanghai 201203,China);Development of Production Procedure and Quality Control Method for Recombinant CHO Cells with Human TypeⅡTumor Necrosis Factor Receptor-Fc Fusion Gene[J];Chinese Journal of Biologicals;2011-01
9 GUO Wei1,ZHANG Jing1,ZHANG Feng1,SHEN Wei-qun2, ZHAO Fang-tao3,XU Yan-ying3,WANG You-chun1 (1.National Institutes for Food and Drug Control,Beijing 100050,China 2.Life Sciences,Peking University,Beijing 100871,China;3.Beijing Institute of Basic Medicine Peking Union Medical College,Beijing 100005,China);Sequencing of amino acids at N-terminus of recombinant antibody[J];Chinese Journal of Pharmaceutical Analysis;2012-06
10 DU Yan-jing,CHEN Di,MU Lin,LIU Zhi-jun(Dept. of Pharmacy,Beijing Hospital of Ministry of Health,Beijing 100730,China);Utilization of Antineoplastics Drugs in Beijing Hospital of Ministry of Health from 2008 to 2010[J];Evaluation and Analysis of Drug-Use in Hospitals of China;2011-11
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved